Dr. Robert M. Levy

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Limbrelâ„¢ (a prescription medical food) taken at 500 mg twice a day was shown to be as effective as naproxen 500 mg taken twice a day for knee osteoarthritis, according to a clinical study presented at the 7th International Cartilage Repair Society (ICRS) World Congress recently held in Warsaw, Poland.1 "In this study, the Limbrel and naproxen groups performed nearly identically, showing significant overall improvements in conventional osteoarthritis efficacy measures, including physician and subject global assessments, and WOMAC, a key measure of mobility, stiffness and joint discomfort," said the lead author Robert Levy, M.D., a rheumatologist for over 30 years and director of clinical development at Primus Pharmaceuticals.

Robert M. (Bob) Levy, M.D. Director of Clinical Development

Dr. Levy is Board Certified in Rheumatology and Internal Medicine and was in private practice in the State of Washington for 30 years.He was the founder and president of the Olympia Arthritis Clinic and Olympia Osteoporosis Center, and the Medical Director of South Sound Clinical Research Center.In the latter capacity, he performed or oversaw more than 200 clinical trials and consulted for the pharmaceutical industry in matters related to early product development, protocol development, and study conduct.Prior to joining Primus, Dr. Levy was the Vice President of Clinical Development for Histatek, Inc., a start-up biotechnology company.Dr. Levy received his MD from the University of Chicago School of Medicine and completed his rheumatology fellowship at the Scripps Clinic & Research Foundation.